goserelin and Atrophy

goserelin has been researched along with Atrophy* in 3 studies

Other Studies

3 other study(ies) available for goserelin and Atrophy

ArticleYear
Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:7

    Topics: Adenocarcinoma; Aged, 80 and over; Alopecia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Fibrosis; Goserelin; Humans; Male; Nitriles; Prostatic Neoplasms; Scalp; Skin; Tosyl Compounds

2018
Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2006, Volume: 96, Issue:9

    Topics: Aged; Antineoplastic Agents, Hormonal; Atrophy; Disease Progression; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Testis; Testosterone; Treatment Failure

2006
Microvascular density in conditions of endometrial atrophy.
    Human reproduction (Oxford, England), 1996, Volume: 11, Issue:9

    Irregular menstrual bleeding in users of hormonal contraception represents the single major reason for discontinuation of these contraceptive methods. The mechanisms which underlie these bleeding disturbances are poorly understood, but appear to be associated with changes in the endometrial microvasculature following abnormal patterns of sex steroid exposure. Endometrial microvascular density is known to be increased in users of the low-dose levonorgestrel contraceptive implant, Norplant. This study explores microvascular density in other conditions of spontaneous (post-menopausal) and induced (danazol and goserelin) endometrial atrophy. Endometrial biopsies were fixed, paraffin-embedded and sections were immunostained using anti-CD34 antibody to identify vascular endothelial cells. The mean microvascular density (+/-SEM) for control samples was 186 +/- 8 vessels/mm2. There were no statistically significant changes in vascular density observed across the menstrual cycle. Mean microvascular density in spontaneous and induced endometrial atrophy did not differ significantly from that observed in the control population. The mean microvascular density was 230 +/- 17 vessels/mm2 in 31 postmenopausal women, 269 +/- 67 vessels/mm2 in 25 subjects treated with danazol was and 191 +/- 45 vessels/mm2 in nine subjects treated with goserelin. These findings suggest that the mechanisms controlling microvascular density in conditions of endometrial atrophy may vary according to the nature of the atrophic stimulus.

    Topics: Adult; Analysis of Variance; Antigens, CD34; Atrophy; Blood Vessels; Danazol; Endometrium; Estrogen Antagonists; Female; Goserelin; Humans; Immunohistochemistry; Microcirculation; Middle Aged; Postmenopause; Staining and Labeling

1996